Pharmaceuticals

Tyche Industries Ltd

Showing the latest 10 filings. Sign in to filter or browse the full history.
10 of 29 filings·Updated 13 Aug 2026
Showing 10 of 29 filings.
13 Aug 20261 filing
Company UpdateNewspaper Publication

Newspaper Publication_ Unaudited Financial Results for the quarter ended June 30, 2026.

Filed 11:25View Source
11 Aug 20261 filing
Board MeetingOutcome of Board Meeting

Tyche Industries approves unaudited quarter ended 30 June 2026 results; auditor notes revenue recognition qualification

Financial results approved

  • Unaudited quarterly results for quarter ended 30 June 2026 approved.
  • Limited Review Report on the results attached.

Auditor remarks

  • Auditors qualify due to Ind AS 115 revenue recognition.
  • Sales dispatched by 30 June 2026 with control not passed; net profit overstated by Rs 48.64 Lakhs.
  • Turnover overstated by Rs 160.43 Lakhs.
Filed 20:34View Source
14 Jul 20261 filing
Company UpdateNewspaper Publication

Newspaper advertisement for the transfer of equity shares of the Company to IEPF pursuant to IEPFA(Accounting, Audit, Transfer and Refund) Rules, 2016

Filed 15:41View Source
7 Jul 20261 filing
Company UpdateCertificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

No dematerialisation requests received for Tyche Industries in quarter ended 30 June 2026

Dematerialisation status

  • RTA confirms no dematerialisation certificates received for Tyche Industries from 1 Apr 2026 to 30 Jun 2026.
  • CIL Securities confirms no dematerialisation requests received from depositories for the quarter ended 30 June 2026.
Filed 17:01View Source
31 May 20261 filing
Company UpdateNewspaper Publication

Newspaper Publication og Audited Financial Results for the 4th Quarter and Year Ended March 31, 2026

Filed 10:53View Source
29 May 20261 filing
Company UpdateReg.24(A)-Annual Secretarial Compliance

Pursuant to Regulation 24A of SEBI(LODR) Regulations, 2015, please find enclosed herewith the Annual Secretarial Compliance Report for the Year ended March 31, 2026.

Filed 10:09View Source
25 Mar 20261 filing
Insider Trading / SASTClosure of Trading Window

The Trading window of the Company shall remain closed w.e.f April 1, 2026, till the expiry of 48 hours after the declaration of the Audited Financial Results of the Company for the quarter ....

Filed 16:24View Source
24 Mar 20261 filing
Company UpdateGeneral

Please find attached the intimation regarding receipt of ANVISA, Brazil GMP certificate for the Company''s Manufacturing facility located at Kakinada, Andhra Pradesh.

Filed 12:24View Source
20 Mar 20262 filings
Insider Trading / SASTDisclosures under Reg. 10(6) of SEBI (SAST) Regulations, 2011

The Exchange has received the disclosure under Regulation 10(6) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for G Ganesh Kumar

Filed 17:58View Source
Company UpdateGeneral

Disclosure under Regulation 10(6) of SEBI(Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for G Ganesh Kumar

Filed 16:30View Source
Showing 10 of 29 filings